{"nctId":"NCT01559012","briefTitle":"Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum","startDateStruct":{"date":"2012-02"},"conditions":["Hyperemesis Gravidarum"],"count":13,"armGroups":[{"label":"clonidine first - placebo second","type":"OTHER","interventionNames":["Drug: Clonidine"]},{"label":"placebo first - clonidine second","type":"OTHER","interventionNames":["Drug: Clonidine"]}],"interventions":[{"name":"Clonidine","otherNames":["Catapresan TTS 2 transdermal patch"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Gestational age 6-12 weeks and a major grade of HG clinical severity defined as follows:\n* a PUQE score index â‰¥ 13 associated to one or more of the following conditions:\n* weight loss \\> 5% of pregravidic weight,\n* electrolyte disturbances,\n* dehydration,\n* duration of symptoms \\> 10 days ,\n* inadequate food and drink intake\n\nExclusion Criteria:\n\n* Language barrier.","healthyVolunteers":false,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PUQE Score for Assessment of Severity in Hyperemesis Gravidarum","description":"PUQE in an acronym for Pregnancy Unique Quantification of Emesis, a validated clinical score for assessment of severity of emesis in pregnancy.\n\nIt is composed of three items; every item has a score from 1 (best) to 5 (worst).\n\nThe sum range varies from 3 (best) to 15 (worst). Participants are followed for the whole duration of hospital stay (10 days) asking them to score their symptoms daily.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"5.5-7.11"},{"groupId":"OG001","value":"8.5","spread":"7.3-9.3"}]}]}]},{"type":"PRIMARY","title":"VAS Score for Assessment of Severity in Hyperemesis Gravidarum","description":"VAS is a Visual Analogic Scale formulated in 5 items. Every item has a score from 0 (best) to 10 (worst). The sum range swings from 0 (best ) to 50 (worst). Participants are followed for the whole duration of hospital stay (10 days) asking them to score their symptoms daily.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"29","spread":"2.58"}]}]}]},{"type":"SECONDARY","title":"Morning Urine Ketonuria","description":"Morning urine ketonuria is a simple direct marker of starving associated to nausea and vomiting","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null},{"groupId":"OG001","value":"0.36","spread":null}]}]}]},{"type":"SECONDARY","title":"Daily Doses of Standard Antiemetic Drugs Required in the Two Different Periods.","description":"The patients were randomly treated with and without TD clonidine (5mg patch) for 2 consecutive periods of 5 days , other antiemetic drugs (promethazine, prochlorperazine, metoclopramide, ondansetron) and anti reflux drugs (ranitidine, omeprazole) being administered on a scheduled or as-needed basis.\n\nAll patients received intravenous hydration and supplementation with thiamine, during both periods. The use of steroids was allowed as a rescue medication in case of further worsening of symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days Off i.v. Therapy, the TD System (Clonidine/Placebo) Being Applied Only","description":"if the symptoms improve the patient and her doctors may decide to stop parenteral drugs continuing the TD system therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":null},{"groupId":"OG001","value":"0.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Choosing Active Treatment for Off-label, Compassionate Use.","description":"the patients were asked to choose between two transdermal systems (active drug versus placebo) as the most effective","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Pregnancy Outcome Measures: Birth Weight.","description":"Birth weight adjusted for gestational age at delivery is a measure of pregnancy outcome after treatment of HG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3312","spread":null}]}]}]},{"type":"SECONDARY","title":"Newborn Outcome Measure: APGAR Score.","description":"The APGAR score is the most common indicator of neonatal status immediately after delivery.\n\nThe test is done by a doctor, midwife, or nurse. The health care provider will examine the baby's:\n\nBreathing effort Heart rate Muscle tone Reflexes Skin color Each category is scored with 0, 1, or 2, depending on the observed condition. The APGAR rating is based on a total score of 1 to 10. The higher the score, the better the baby is doing after birth.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Systolic Blood Pressure","description":"Systolic BP was measured every day during the clonidine treatment (5 days) and placebo (5 days)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]}]},{"type":"SECONDARY","title":"Diastolic Blood Pressure","description":"Diastolic BP was recorded every day during clonidine (5 days) and placebo (5 days) cycle","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":6},"commonTop":["Itching"]}}}